ombitasvir/paritaprevir/ritonavir (Viekira, Technivie)
Jump to navigation
Jump to search
Indications
- hepatitis C infection genotype 1 (AbbVie, Viekira)
- for use in combination with dasabuvir (Viekira Pack)
- hepatitis C infection genotype 4 without cirrhosis ((Technivie)
- for use in combination with ribavirin
Contraindications
- concurrent use of ethinyl estradiol
- moderate to severe hepatic impairment (Child-Pugh class B & C)
Adverse effects
- fatigue
- asthenia
- nausea,
- insomnia
- pruritus & other skin reactions
- hepatoxicity[3]
- elevated serum transaminases (5-fold elevation in 1%)
- reactivation of hepatitis B in patients with current or previous hepatitis B infection[5]
- 24% of patients with chronic hepatitis B[6]
- 1.4% with resolved hepatitis B infection[6]
Drug interactions
- contraceptives containing ethinyl estradiol increase likelihood of increased serum transaminases
- proton pump inibitors have no effect on efficacy[4]
- drug interaction(s) of antiretroviral protease inhibitor in combination with ritonavir
- drug interaction(s) of boceprevir in combination with ritonavir & Kaletra
- drug interaction(s) of boceprevir in combination with ritonavir & darunavir
- drug interaction(s) of boceprevir in combination with ritonavir & atazanavir
- drug interaction(s) of saquinavir with ritonavir
- drug interaction(s) of eplerenone with ritonavir
Notes
- manufacturer: Abbvie
More general terms
Additional terms
Components
References
- ↑ Brooks M FDA Clears Two New Oral Drugs for Hepatitis C. Medscape Oncology. July 24, 2015 http://www.medscape.com/viewarticle/848650
- ↑ FDA News Release. July 24, 2015. FDA approves Technivie for treatment of chronic hepatitis C genotype 4. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm455857.htm
- ↑ 3.0 3.1 Brown T Viekira Pak, Technivie May Up Serious Liver Injury Risk: FDA. Medscape Oncology. Oct 22, 2015 http://www.medscape.com/viewarticle/853126
FDA Safety Alert. 10/22/2015 Hepatitis C Treatments Viekira Pak and Technivie: Drug Safety Communication - Risk of Serious Liver Injury. http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm468757.htm - ↑ 4.0 4.1 Shiffman ML et al. Safety and efficacy of ombitasvir/paritaprevir/ritonavir plus dasabuvir with or without ribavirin in HCV-infected patients taking concomitant acid-reducing agents. Am J Gastroenterol 2016 Apr 5 PMID: https://www.ncbi.nlm.nih.gov/pubmed/27045929
- ↑ 5.0 5.1 FDA Drug Safety Communication: Oct 4, 2016 FDA warns about the risk of hepatitis B reactivating in some patients treated with direct-acting antivirals for hepatitis C. http://www.fda.gov/Drugs/DrugSafety/ucm522932.htm
- ↑ 6.0 6.1 6.2 Mucke MM, Backus LI, Mucke VT et al Hepatitis B virus reactivation during direct-acting antiviral therapy for hepatitis C: a systematic review and meta-analysis. Lancet Gastroenterology & Hepatology. Jan 19, 2018 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/29371017 <Internet> http://www.thelancet.com/journals/langas/article/PIIS2468-1253(18)30002-5/fulltext